Abstract:Purpose: To investigate the neuroprotective effects of scutellarin, an active component of the multifunctional traditional Chinese herb Erigeron breviscapus (vant.) Hand.-Mazz. (EBHM), which has been used as a neuroprotective therapy for cerebrovascular diseases. We performed the experiments using in vitro and in vivo models of retinal neurodegeneration. Methods: In the in vitro experiments, we exposed BV-2 cells to low oxygen levels in an incubator for 24 and 48 h to generate hypoxia models. We then treated these cells with scutellarin at concentrations of 2, 10, and 50 mu M. Cell viability was measured using an enzyme-linked immunosorbent assay (ELISA). The levels of the components of the nucleotidebinding oligomerization domain, leucine-rich repeat and pyrin domain containing 3 (NLRP3) inflammasome signaling pathway, including NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), cleaved caspase-1, interleukin-18 (IL-18), and IL-1 beta were analyzed using western blots and ELISAs. In the in vivo study, we raised the intraocular pressure of Brown Norway rats to 60 mmHg for 30 min to generate a high intraocular pressure (HIOP) model, that is, an acute glaucoma model. The rats were then treated with scutellarin via oral gavage for 2 consecutive weeks. The relevant components of the NLRP3 inflammasome signaling pathway were analyzed with western blots and ELISAs. Retinal ganglion cells (RGCs) were retrogradely labeled using 4% Fluoro-Gold, and then the numbers of cells were calculated. Retinal microglial cells were labeled using immunofluorescence, and then the morphological changes were observed. Results: In the in vitro cell viability experiments, 50 mu M scutellarin statistically significantly enhanced the viability rate when compared to 2 mu M and 10 mu M scutellarin (hypoxia + 50 mu M EBHM group: 94.01 +/- 2.130% and 86.02 +/- 2.520% after 24 and 48 h, respectively; hypoxia model group: 74.98 +/- 3.860% and 64.41 +/- 4.890% after 24 and 48 h, respectively; for all when compared to normal control, p<0.001). Scutellarin inhibited the expression of NLRP3 in vitro (the hypoxia + EBHM group/normal control group ratio versus the hypoxia model group/normal control group ratio: 2.30 +/- 0.12 versus 4.06 +/- 0.19, p<0.01) and in vivo (the HIOP + EBHM group/normal control group ratio versus the HIOP model group/normal control ratio: 3.39 +/- 0.42 versus 6.07 +/- 0.22, p<0.01). Scutellarin administration also reduced the upregulation of ASC, cleaved caspase-1, IL-18, and IL-1 beta in vitro and in vivo. In the in vivo study, the RGC survival rate was statistically significantly improved following scutellarin administration (p<0.001 versus the HIOP group), and the number of impaired retinal microglial cells was statistically significantly reduced following scutellarin treatment when compared with the HIOP model group. Conclusions: EBHM extract scutellarin exhibits protective effects in retinal hypoxia models by inhibiting NLRP3 inflammasome-mediated inflammatory reactions. Thus, EBHM extract scutellarin may be an appropriate therapeutic option for disorders related to retinal neurodegeneration, such as glaucoma.

GW29-e0482 Scutellarein Protects Against Phenylephrine-Induced Cardiac Hypertrophy in H9C2 and AC16 by TRAF2/NF-κB Signaling Pathway

Scutellarein Protects Against Cardiac Hypertrophy Via Suppressing TRAF2/NF-κB Signaling Pathway

Scutellarin Protects Myocardial Ischemia-Reperfusion Injury ERK1/2-CREB Regulated Mitophagy

Protective Effects of Erigeron Breviscapus Hand.- Mazz. (EBHM) Extract in Retinal Neurodegeneration Models.

Anti-Fibrosis Effect of Scutellarin via Inhibition of Endothelial–Mesenchymal Transition on Isoprenaline-Induced Myocardial Fibrosis in Rats

Scutellarein Suppresses the Production of ROS and Inflammatory Mediators of LPS-Activated Bronchial Epithelial Cells and Attenuates Acute Lung Injury in Mice

Scutellarin alleviates tensile stress-induced proliferation and migration of venous smooth muscle cells via mediating the p38 MAPK pathway

Review on the pharmacological effects and pharmacokinetics of scutellarein

Scutellarein Inhibits BLM-mediated Pulmonary Fibrosis by Affecting Fibroblast Differentiation, Proliferation, and Apoptosis

Effects of Scutellarin on the Proliferation of Cardiac Fibroblasts in Neonate Rats Induced by Angiotensin Ⅱ and Signal Pathway of ERK1/2 and p38 MAPK

Protection of Scutellarein on Cerebral Ischemia in Rats

Scutellarein ameliorates dextran sulfate sodium-induced ulcerative colitis by inhibiting colonic epithelial cell proinflammation and barrier disruption

Effects of Scutellarein on Diabetic Rat Aorta

The Effects of Scutellarein on Platelet Cytosolic Free Calciumconcentration,platelet Aggregation Rate,and Heart Remodeling in Rats

Scutellarin Attenuates Hypertension-Induced Expression of Brain Toll-Like Receptor 4/nuclear Factor Kappa B

Scutellarein inhibits lung cancer growth by inducing cell apoptosis and inhibiting glutamine metabolic pathway

Pharmacological effects and the related mechanism of scutellarin on inflammation-related diseases: a review

Scutellarein Selectively Targets Multiple Myeloma Cells by Increasing Mitochondrial Superoxide Production and Activating Intrinsic Apoptosis Pathway.

Protective Effects of Scutellarin Against Cerebral Ischemia in Rats: Evidence for Inhibition of the Apoptosis-Inducing Factor Pathway

Scutellarein Inhibits Hypoxia- and Moderately-High Glucose-Induced Proliferation and VEGF Expression in Human Retinal Endothelial Cells

Scutellarin Prevents Nonalcoholic Fatty Liver Disease (NAFLD) and Hyperlipidemia via PI3K/AKT-Dependent Activation of Nuclear Factor (Erythroid-Derived 2)-Like 2 (Nrf2) in Rats